MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
Testing for BRCA mutations in prostate cancer
Prostate /
LYNPARZA® (olaparib) /
Training and Resources /
Root /

Testing for BRCA mutations in prostate cancer

Great Britain prescribing information
Northern Ireland prescribing information

Length: 02:39

On 26 January 2021, AstraZeneca and MSD organised a webcast on challenging the treatment paradigm for mCRPC with precision medicine in UK practice. You can watch a recording of this webcast with Dr Simon Crabb discussing the prevalence of BRCA1 and BRCA2 mutations in metastatic Castrate Resistant Prostate Cancer (mCRPC), as well as discussing how and when to test prostate cancer patients for the BRCA1 or BRCA2 mutations.

More information about LYNPARZA™ (olaparib) in Prostate Cancer:

LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1

Visit product page

The PROfound trial: efficacy and safety data

The PROfound trial: study design

Reference

  1. LYNPARZA (tablets) Summary of Product Characteristics.

Supporting documentation

100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-28508 | Date of Preparation: June 2021